Profile
Sector:
HealthcareIndustry:
Drug Manufacturers - GeneralCountry:
United StatesIPO:
22 January 1992Website:
http://www.gilead.comNext earnings report:
06 November 2024Last dividends:
13 September 2024Next dividends:
N/APrice
regular market | 8 min agoAnalysts recommendations
Institutional Ownership
GILD Latest News
Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Gilead Sciences (GILD) closed at $88.08 on the most recent trading day, showing a decrease of 0.77% from its previous closing price.
These stocks are being sold for under 15 times what they are predicted to earn in the future.
At the end of the last trading day, Gilead Sciences (GILD) was priced at $87.23, which represents a decrease of 1.05% compared to the day before.
On Friday, Gilead Sciences announced that it is choosing to withdraw the U.S. approval for Trodelvy, which is used for patients with a specific type of urothelial cancer who have already received treatment. This decision was made after discussions with the regulatory authorities.
Leading analysts on Wall Street have updated their opinions on these major companies. To see all the changes in analyst ratings, including both upgrades and downgrades, visit our analyst ratings page.
Gilead Sciences (GILD) closed at $85.83 on the most recent trading day, showing an increase of 0.91% from its previous closing price.
GILD's latest positive results on lenacapavir highlight the drug's possible effectiveness in preventing HIV among the specific group of people.
Gilead Sciences (GILD) closed at $85.21 on the most recent trading day, showing an increase of 0.92% from its previous closing price.
Gilead's lenacapavir could become a major HIV prevention drug. Biktarvy continues to hold a large share of the HIV treatment market, which helps boost Gilead's earnings. Additionally, Gilead's cancer treatment division is growing, with Trodelvy and Yescarta showing promise for increased sales.
What type of business is Gilead Sciences?
Gilead Sciences, Inc. is an American research-based biopharmaceutical company founded in 1987 with headquarters in Foster City, California. The company is engaged in the search, development, and commercialization of innovative drugs for serious diseases such as HIV, AIDS, liver disease, hematology, oncology, and respiratory diseases. The company produces a wide range of products under its own brands, including AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Epclusa, Genvoya, Harvoni, Hepsera, Letairis, Odefsey, Ranexa, Sovaldi, Stribild, Tybost, Vemlidy, Vosevi, Yescarta, Zydelig, and others. The existing product portfolio is constantly being supplemented and expanded through the company's ongoing research and development, licensing, and strategic partnerships.
What sector is Gilead Sciences in?
Gilead Sciences is in the Healthcare sector
What industry is Gilead Sciences in?
Gilead Sciences is in the Drug Manufacturers - General industry
What country is Gilead Sciences from?
Gilead Sciences is headquartered in United States
When did Gilead Sciences go public?
Gilead Sciences initial public offering (IPO) was on 22 January 1992
What is Gilead Sciences website?
https://www.gilead.com
Is Gilead Sciences in the S&P 500?
Yes, Gilead Sciences is included in the S&P 500 index
Is Gilead Sciences in the NASDAQ 100?
Yes, Gilead Sciences is included in the NASDAQ 100 index
Is Gilead Sciences in the Dow Jones?
No, Gilead Sciences is not included in the Dow Jones index
When was Gilead Sciences the previous earnings report?
No data
When does Gilead Sciences earnings report?
The next expected earnings date for Gilead Sciences is 06 November 2024